Inferra AI / Company / UTHR
United Therapeutics
UTHR · Health Care
Last earnings Aug 5, 2026
Key results
Total revenuequarter
$783.3 million
Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
Total Tyvaso revenuequarter
$452.6 million
Total Tyvaso revenues decreased by four percent to $452.6 million in the second quarter of 2026, compared to $469.6 million in the second quarter of 2025, driven by a decrease in Nebulized Tyvaso revenues, partially offset by growth in Tyvaso DPI revenues.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
Tyvaso DPI revenuequarter
$6.9 million
The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold of $6.9 million and a price increase of $9.4 million, partially offset by higher gross-to-net deductions.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
AI analysis
Q2 2026 · reported Aug 5, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $783.3 million | — | $798.6 million |
| Total Tyvaso revenue | $452.6 million | — | $469.6 million |
| Tyvaso DPI revenue | $6.9 million | — | — |
Guidance · company-stated
No guidance located in the held release
Capital allocation
The decrease in interest income was primarily due to a decrease in marketable investments due to the sale of securities to fund our two accelerated share repurchase agreements in March 2026 (the 2026 ASR agreements ).
In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock, which expires on March 9, 2027.
Event summary
United Therapeutics Q2 2026 — Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025.
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The decrease in interest income was primarily due to a decrease in marketable investments due to the sale of securities to fund our two accelerated share repurchase agreements in March 2026 (the 2026 ASR agreements ).
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock, which expires on March 9, 2027.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
to repurchase approximately $1.5 billion of our common stock.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
In total, we repurchased 2,759,343 shares of our common stock under the 2026 ASR agreements, of which 2,543,395 were held as treasury stock in our consolidated balance sheets as of June 30, 2026.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
As of June 30, 2026, $500 million remained available under the share repurchase program authorized by our Board for purchases through March 9, 2027.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
During the three and six months ended June 30, 2025, the tax (benefit) expense in other comprehensive income was $( 0.1 ) million for the defined benefit pension plan and $ 0.5 million and $ 2.2 million, respectively, for the available-for-sale debt securities.
SEC original ↗United Therapeutics — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
Organization and Business Description United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
SEC original ↗United Therapeutics — 10-Q Quarterly report10-QAug 5, 2026
Our operating segment focuses on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions.
SEC original ↗United Therapeutics — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
The increase in general and administrative expense for the three months ended June 30, 2026, as compared to the same period in 2025, was primarily due to (1) an increase in personnel expense due to growth in headcount and (2) an increase in consulting expenses, partially offset by a decrease in legal expenses related to litigation matters.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from an ticipated results.
SEC original ↗United Therapeutics — Earnings release (8-K exhibit)EX-99Aug 5, 2026
Legal Proceedings 42 Item 1A.
SEC original ↗United Therapeutics — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q3 2026
- 8-KUTHR
Oct 14, 2026
- Q2 2026
- 8-KUTHR
Sep 8, 2026
- 8-KUTHR
Aug 5, 2026
- 10-QUTHR
Aug 5, 2026
- 8-KUTHR
Jul 23, 2026
- Q1 2026
- 8-KUTHR
Jun 29, 2026
- 8-KUTHR
May 6, 2026
- 10-QUTHR
May 6, 2026
- Q4 2025
- 8-KUTHR
Mar 30, 2026
- 8-KUTHR
Mar 9, 2026
- 8-KUTHR
Mar 2, 2026
- 8-KUTHR
Feb 25, 2026
- 10-KUTHR
Feb 25, 2026
- 8-KUTHR
Jan 22, 2026
- EX-99UTHR
Jan 22, 2026
- Q3 2025
- 8-KUTHR
Oct 29, 2025
- 10-QUTHR
Oct 29, 2025
- Q2 2025
- 8-KUTHR
Sep 2, 2025
- 8-KUTHR
Aug 1, 2025
- 8-KUTHR
Jul 30, 2025
- 10-QUTHR
Jul 30, 2025
- Q1 2025
- 8-KUTHR
Jun 27, 2025
- 8-KUTHR
Apr 30, 2025
- 10-QUTHR
Apr 30, 2025
- 8-KUTHR
Apr 28, 2025
- Q4 2024
- 8-KUTHR
Feb 26, 2025
- 10-KUTHR
Feb 26, 2025
- 8-KUTHR
Jan 13, 2025
- Q3 2024
- 8-KUTHR
Oct 30, 2024
- 10-QUTHR
Oct 30, 2024
- Q2 2024
- 8-KUTHR
Jul 31, 2024
Earnings releases
10 documentsPresentations
0 documentsNo presentations for United Therapeutics are held in this edition of the library.
Transcripts
0 documentsNo transcripts for United Therapeutics are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention United Therapeutics by name or ticker. A mention is counted once per document, from the document text the library holds.
“bit 99.1 Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH · Fully resolves… …ruling by the U.S. District Court for the District of De”
See also the earnings calendar for every tracked company’s next earnings date.